The Human Papillomavirus (HPV) CERVAVAC vaccine, for the prevention of cervical cancer, is expected to arrive in India by April at the one-tenth of the cost of internationally branded vaccines in the country, said Dr NK Arora, chairman of the Covid working group, National Technical Adviso
Cervical cancer is mostly related to human papillomavirus (HPV), and screening has made this cancer preventable. Yet, it is estimated that over 14,000 new cases will be diagnosed this year and more than 4,000 deaths will be attributed to cervical cancer.
To create Awareness among women and to fight against Cancer, an awareness program was organised in Odisha's Bhubaneshwar at the backdrop of Dhauli Shanti stupa, The place where the Kalinga war of Ashoka fought.
India will soon introduce the human papillomavirus (HPV) vaccination to eliminate cervical cancer as a public health problem, said Dr Poonam Khetrapal Singh, World Health Organization (WHO) Regional Director for South-East Asia.
San Antonio [US], October 23 (ANI): According to a new study, sexual side effects of cancer therapy are discussed considerably less frequently in female patients than in male patients, even when the medication directly affects genital organs. In a high-volume cancer facility, 9 out of 10 mal
New Delhi [India], October 21 (ANI): The production of India's first indigenously developed quadrivalent Human Papillomavirus (HPV) "CERVAVAC" vaccine, for the prevention of cervical cancer, by the Serum Institute of India will start in the first quarter of 2023 which got delayed due to C
Gurugram (Haryana) [India], September 13 (ANI/BusinessWire India): Cervical cancer is the fifth most common cancer among women globally according to World Health Organization (WHO). India accounts for one-fifth (1/5th) of the global burden of the disease. Every year in India, approximatel
New Delhi [India], September 1 (ANI: India's first indigenously developed quadrivalent Human Papilloma Virus (qHPV) vaccine will be available at an affordable price, said Serum Institute of India (SII) CEO Adar Poonawala on Thursday.
New Delhi [India], August 31 (ANI): The Serum Institute of India (SII) and the Department of Biotechnology(DBT) are set to launch India's first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) against Cervical Cancer on September 1, official sources told ANI.
New Delhi [India], July 12 (ANI): India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer gets Drugs Controller General of India (DCGI) approval for market authorisation. This vaccine will be manufactured by the Serum Institute of India (SII).
New Delhi [India], June 28 (ANI): The National Technical Advisory Group on Immunisation (NTAGI) reviewed the data and recommended the vaccination for Typhoid and Cervical Cancer, said sources on Tuesday.